# Medical - Specialties — company-by-company sector analysis > Medical - Specialties: Shoulder Innovations, Inc. owns the largest revenue base AND the fastest current growth. Sector Alpha — machine-written from the numbers. Data as of 2026-08-20. Not investment advice. ## Bottom line Medical - Specialties has outperformed S&P 500 by 47.1% over 52 weeks and 48% over 13 weeks. 1 of 1 covered companies beat the S&P 500 on Mansfield relative strength, while 0 of 1 beat the sector itself. Shoulder Innovations, Inc. leads with revenue of $54 million, based on 1 of 1 comparable companies through Mar 2026. ## Sector relative strength Medical - Specialties has outperformed S&P 500 by 47.1% over the last 52 weeks. Over 13 weeks the gap is a lead of 48%. 1 of 1 covered company currently beats the S&P 500 on Mansfield relative strength, so leadership inside the sector is selective. Shoulder Innovations, Inc. is the strongest against the sector itself at 0%. 13-week sector return versus NIFTY 500: 48% 52-week sector return versus NIFTY 500: 47% Stocks leading NIFTY: 1/1 Stocks leading sector: 0/1 Central tension: The central tension: current leadership is concentrated, so durability matters more than rank. Companies: 1 Combined market value: ₹460 Cr ## 4-Factor Sector Score An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment. 1. Shoulder Innovations, Inc. (SI): 46/100 — Thin evidence · provisional; evidence 58% - Growth & earnings 20.3/35 | Capital efficiency 3.0/25 | Valuation 10.0/20 | Relative strength 12.5/20 - Price stage: BREAKING OUT — Ahead of the benchmark five weeks or more running, with its lead holding or widening. - Led NIFTY 500 by 5%+ over the prior 13 weeks in 11 of the last 12 weeks - Exact sum: 20.3 + 3 + 10 + 12.5 = 45.8 - Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. ## Market action Shoulder Innovations, Inc. has the strongest one-year price move in Medical - Specialties at +73.9%. It also leads on Mansfield relative strength against the S&P 500 at +31.7%. 1 of 1 covered company is above zero on that measure. Every line covers 314 weekly closes through 2026-08-20. ### Strongest one-year price performers 1. Shoulder Innovations, Inc. (SI): 74% ### Strongest relative strength versus NIFTY 500 1. Shoulder Innovations, Inc. (SI): 32% ## Revenue Scale & Growth Durability What the numbers say: Shoulder Innovations, Inc. is the scale leader at $54 million, Shoulder Innovations, Inc.'s growth is 58.8% from a $54 million base, with 9 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale. Investor read: Shoulder Innovations, Inc. is the scale benchmark; Shoulder Innovations, Inc. is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns. This conclusion weakens if: Shoulder Innovations, Inc.'s growth falls below Shoulder Innovations, Inc.'s for two consecutive comparable reports while operating margin also compresses. Evidence: Shoulder Innovations, Inc. · $54 million | Not enough peers | 5/5 recent comparable periods | 1/1 companies · 9 observations Definition: Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress. ### Revenue — largest 1. Shoulder Innovations, Inc. (SI): ₹54 Cr ### Revenue growth — fastest growers 1. Shoulder Innovations, Inc. (SI): 59% ### 11-quarter Revenue history - SI: Sep 2023 — | Dec 2023 — | Mar 2024 ₹7 Cr | Jun 2024 ₹8 Cr | Sep 2024 ₹7 Cr | Dec 2024 ₹9 Cr | Mar 2025 ₹10 Cr | Jun 2025 ₹11 Cr | Sep 2025 ₹12 Cr | Dec 2025 ₹14 Cr | Mar 2026 ₹17 Cr ### 11-quarter Revenue growth history - SI: Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 43% | Jun 2025 38% | Sep 2025 71% | Dec 2025 56% | Mar 2026 70% ## Operating Economics & Margin Trend What the numbers say: Shoulder Innovations, Inc. leads both opm at -53.7% and margin change at -11.3 percentage points. Investor read: Shoulder Innovations, Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it. This conclusion weakens if: The next two comparable reports reverse the current margin change signal. Evidence: Shoulder Innovations, Inc. · -53.7% | Not enough peers | 1/5 recent comparable periods | 1/1 companies · 9 observations Definition: Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth. ### OPM — highest 1. Shoulder Innovations, Inc. (SI): -54% ### Margin change — fastest expanders 1. Shoulder Innovations, Inc. (SI): −11.3 pp ### 11-quarter OPM history - SI: Sep 2023 — | Dec 2023 — | Mar 2024 -45% | Jun 2024 -48% | Sep 2024 -52% | Dec 2024 -41% | Mar 2025 -42% | Jun 2025 -53% | Sep 2025 -65% | Dec 2025 -59% | Mar 2026 -54% ### 11-quarter Margin change history - SI: Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 +2.9 pp | Jun 2025 −5.0 pp | Sep 2025 −12.9 pp | Dec 2025 −18.5 pp | Mar 2026 −11.3 pp ## Profit Scale & Acceleration What the numbers say: Shoulder Innovations, Inc. leads net profit at $44 million net cash; the second comparison lacks enough current evidence. Investor read: Shoulder Innovations, Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it. This conclusion weakens if: The next two comparable reports reverse the current profit growth signal. Evidence: Shoulder Innovations, Inc. · $44 million net cash | Not enough peers | Not enough history | 1/1 companies · 9 observations Definition: Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank. ### Net profit — largest 1. Shoulder Innovations, Inc. (SI): ₹-44 Cr ### Profit growth — fastest growers ### 11-quarter Net profit history - SI: Sep 2023 — | Dec 2023 — | Mar 2024 ₹-4 Cr | Jun 2024 ₹-4 Cr | Sep 2024 ₹-4 Cr | Dec 2024 ₹-4 Cr | Mar 2025 ₹-5 Cr | Jun 2025 ₹-19 Cr | Sep 2025 ₹-9 Cr | Dec 2025 ₹-8 Cr | Mar 2026 ₹-8 Cr ### 11-quarter Profit growth history ## Return On Capital Employed What the numbers say: Shoulder Innovations, Inc. leads ROCE at -9%. Shoulder Innovations, Inc. has the strongest latest improvement at +8 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability. Investor read: Shoulder Innovations, Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it. This conclusion weakens if: The next two comparable reports reverse the current roce change signal. Evidence: Shoulder Innovations, Inc. · -9% | Not enough peers | 2/5 recent comparable periods | 1/1 companies · 9 observations Definition: ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability. ### ROCE — highest 1. Shoulder Innovations, Inc. (SI): -9.0% ### ROCE change — fastest improvers 1. Shoulder Innovations, Inc. (SI): +8.0 pp ### 11-quarter ROCE history - SI: Sep 2023 0.0% | Dec 2023 0.0% | Mar 2024 — | Jun 2024 — | Sep 2024 -9.1% | Dec 2024 -8.3% | Mar 2025 -17% | Jun 2025 -18% | Sep 2025 -7.7% | Dec 2025 -8.9% | Mar 2026 -9.0% ### 11-quarter ROCE change history - SI: Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 −9.1 pp | Dec 2024 −8.3 pp | Mar 2025 — | Jun 2025 — | Sep 2025 +1.4 pp | Dec 2025 −0.6 pp | Mar 2026 +8.0 pp ## Valuation Against Growth & Quality What the numbers say: There is not enough comparable evidence to name a reliable peg leader. Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy. This conclusion weakens if: The next two comparable reports reverse the current p/e signal. Evidence: No comparable leader | Not enough peers | Not enough history | 0/1 companies · 0 observations Definition: PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing. ### PEG — lowest PEG ### P/E — lowest P/E ### 11-quarter PEG history ### 11-quarter P/E history ## What can make this comparison misleading? - A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason. - A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment. - The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed. - An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion. - Thin comparisons: Valuation have fewer than three usable current readings. ## Every company - Shoulder Innovations, Inc. (SI) — market value ₹460 Cr; latest fundamentals Mar 2026 ## Methodology and freshness Fundamentals through Mar 2026; prices through 2026-08-20. Up to 11 quarters per company. Reported history is normalized to Indian rupees crore. Missing values are not interpolated. Derived metrics are calculated only when their inputs are comparable. ## Frequently asked questions ### Is the Medical - Specialties sector outperforming S&P 500? Medical - Specialties has outperformed S&P 500 by 47.1% over 52 weeks and 48% over 13 weeks. 1 of 1 covered companies beat the S&P 500 on Mansfield relative strength, while 0 of 1 beat the sector itself. ### Which Medical - Specialties company is largest by revenue? Shoulder Innovations, Inc. leads with revenue of $54 million, based on 1 of 1 comparable companies through Mar 2026. ### Which Medical - Specialties company is growing fastest? Shoulder Innovations, Inc. has the fastest current revenue growth at 58.8%, across 1 of 1 comparable companies. ### Which Medical - Specialties company has the strongest 4-Factor Sector Score? Shoulder Innovations, Inc. ranks first at 45.8/100 with 57.7% evidence confidence. The score prioritizes research; it is not a buy recommendation. ### How much history does this Medical - Specialties comparison include? The page compares up to 11 reported quarters per company for fundamentals, returns and valuation, ending Mar 2026. Missing observations remain blank rather than being estimated. ### How is the 4-Factor Sector Score calculated? The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral. ### Which Medical - Specialties company is the biggest? Shoulder Innovations, Inc. is the largest, with trailing-twelve-month revenue of $54 million. That covers 1 of 1 companies with comparable reporting through Mar 2026. ### Which Medical - Specialties company has the best profit margins? Shoulder Innovations, Inc. has the highest operating margin at -53.7%, from 1 of 1 comparable companies. Shoulder Innovations, Inc. shows the biggest recent improvement, at -11.3 percentage points. A high margin matters most when it is holding or rising, not when it is peaking. ### Which Medical - Specialties company makes the most profit? Shoulder Innovations, Inc. earns the most, at $44 million of trailing-twelve-month net profit, from 1 of 1 comparable companies. ### Which Medical - Specialties company earns the highest return on capital? Shoulder Innovations, Inc. leads on return on capital employed at -9%, across 1 of 1 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year. ### Is the Medical - Specialties sector beating the market? Medical - Specialties has outperformed S&P 500 by 47.1% over the last 52 weeks and 48% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 1 of 1 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it. ### Which Medical - Specialties stock has the strongest price momentum? Shoulder Innovations, Inc. has the strongest relative strength against S&P 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all. ### Which Medical - Specialties company scores highest for research priority? Shoulder Innovations, Inc. scores 45.8 out of 100 with 57.7% evidence confidence, from 20.3 points on growth and earnings, 3 on capital efficiency, 10 on valuation and 12.5 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research. ### How many Medical - Specialties companies does this comparison cover, and over what period? It compares 1 listed companies over up to 11 reported quarters of fundamentals, ending Mar 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data. ### What is the total market cap of the Medical - Specialties sector? The 1 Medical - Specialties companies on this page carry $460 million of combined market value. Shoulder Innovations, Inc. is the largest at $460 million, about 100% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-20. ### How is the Medical - Specialties sector performing? 1 of the 1 covered Medical - Specialties companies are beating S&P 500 on Mansfield relative strength. The sector itself is 47.1% ahead of S&P 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-20. ### How many Medical - Specialties stocks are listed in the US? This comparison covers 1 listed Medical - Specialties companies in the US, each above the size floor the site applies. The full ranked list is on this page, with reported fundamentals through Mar 2026. Membership is the full industry list — nothing is dropped for having thin data. ### Why are some values on this page blank? A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad. ### Is this investment advice? No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.